FGF19 and hepatocellular carcinoma: The release of fibroblast growth factor 19 subsequently activated the JAK 2/STAT 3 signaling pathway, promoting the epithelial-mesenchymal transition in HCC cells and significantly enhancing their migratory, invasive, and metastatic capabilities [70].